

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

Bcr Antibody

RRID:AB_2063777

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3902, RRID:AB_2063777

Antibody Information

URL: http://antibodyregistry.org/AB_2063777

Proper Citation: Cell Signaling Technology Cat# 3902, RRID:AB_2063777

Target Antigen: Bcr

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W. Consolidation on 10/2018: AB_10693751, AB_2063777.

Antibody Name: Bcr Antibody

Description: This polyclonal targets Bcr

Target Organism: rat, h, porcine, m, mouse, r, pg, human

Antibody ID: AB_2063777

Vendor: Cell Signaling Technology

Catalog Number: 3902

Record Creation Time: 20250820T024552+0000

Record Last Update: 20250820T142720+0000

Ratings and Alerts

No rating or validation information has been found for Bcr Antibody.

No alerts have been found for Bcr Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang H, et al. (2023) The Evaluation of Rac1 Signaling as a Potential Therapeutic Target of Alzheimer's Disease. International journal of molecular sciences, 24(15).

Wei L, et al. (2020) A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway. Molecular therapy oncolytics, 18, 137.

Eide CA, et al. (2019) Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer cell, 36(4), 431.